Key Takeaways
- Pfizer CEO Albert Bourla told the company’s Q1 2025 earnings call that he remains “cautiously optimistic” about the pharma industry’s position in terms of US tariff, drug pricing and other relevant policies based on ongoing talks with the Trump Administration.
CEO Albert Bourla, during Pfizer’s first quarter 2025 earnings presentation on 29 April, said the company remains in close communication...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?